B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

NCOA3

MOLECULAR TARGET

nuclear receptor coactivator 3

UniProt: Q9Y6Q9NCBI Gene: 820217 compounds

NCOA3 (nuclear receptor coactivator 3) is targeted by 17 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting NCOA3

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Methylene Blue1.614
2alsterpaullone1.102
3Methotrexate1.102
4Anisomycin1.102
5Azacitidine1.102
6Azacitidine1.102
7Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.1.102
8Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.1.102
9Digoxin1.102
10Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.1.102
11Tubercidin1.102
12tyrphostin 91.102
13cycloheximide0.691
14Cytarabine0.691
15Lanatosides Glycosides from DIGITALIS lanata leaf. Lanatoside C has actions similar to DIGOXIN. Mixtures of lanatosides A, B, and C have also been used. (From Martindale,0.691
16Trifluridine0.691
17urolithin b0.691

About NCOA3 as a Drug Target

NCOA3 (nuclear receptor coactivator 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 17 compounds with documented NCOA3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

NCOA3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.